Latest from the CoBRIM study
5 Nov 2015
Latest from the CoBRIM study
Anti-PD-1 or anti-CTLA-4 in first line therapy?
Long response and long responders in melanoma immunology
What is the real role of UV in melanoma?
The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma
Benefit and risk analysis from the phase III OPTiM trial
Progress in targeted therapy of melanoma
Why is screening for melanoma important?
Management of acute metastatic melanoma
How should we handle talimogene laherparepvec (T-VEC)?
New challenges in drug combination and strategies
Editor's choice for October 2015